Market research
AC8.AU AusCann Group Holdings Ltd
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 18M
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.8
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- AU000000AC89
- Market cap
- 18M
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.8
About
About AusCann Group Holdings Ltd
AusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. Its principal product includes the novel tetrahydrocannabinol and cannabidiol (THC/CBD), a powder-based hard-shell capsules based on AusCann's Neuvis platform for the treatment of pain and related indications. The company is also involved in the research and development of medicinal cannabis. It offers its products to healthcare professionals and veterinarians. AusCann Group Holdings Ltd is based in West Perth, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AC8.AU discussion.
5 years, 6 months ago
AusCann Group Holdings Ltd is currently in a long term downtrend where the price is trading 27.9% below its 200 day moving average.
From a valuation standpoint, the stock is 6050.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 15832.4.
AusCann Group Holdings Ltd's total revenue sank by 64.2% to $92K since the same quarter in the previous year.
Its net income has dropped by 34.3% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 68.1% to $-2M since the same quarter in the previous year.
Based on the above factors, AusCann Group Holdings Ltd gets an overall score of 1/5.